FM
TRIB

Fondren Management’s Trinity Biotech TRIB Stock Holding History

Fondren Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-46,000
Closed -$253K – 54
2020
Q1 		$253K Sell
46,000
-141,720
-75% -$742K 0.64% 41
2019
Q4 		$970K Buy
187,720
+43,720
+30% +$208K 0.99% 27
2019
Q3 		$871K Buy
144,000
+68,000
+89% +$591K 0.72% 40
2019
Q2 		$627K Buy
76,000
+2,524
+3% +$30K 0.6% 44
2019
Q1 		$1.05M Buy
73,476
+6,116
+9% +$84.1K 0.83% 30
2018
Q4 		$771K Buy
67,360
+38,360
+132% +$592K 1.01% 26
2018
Q3 		$580K Buy
29,000
+2,000
+7% +$43.5K 0.52% 40
2018
Q2 		$675K Buy
27,000
+7,000
+35% +$168K 0.52% 51
2018
Q1 		$515K Hold
20,000
– – 0.65% 30
2017
Q4 		$510K Buy
+20,000
New +$516K 0.36% 38
2017
Q3 		– Sell
-18,000
Closed -$540K – 65
2017
Q2 		$540K Sell
18,000
-64,000
-78% -$1.81M 0.59% 26
2017
Q1 		$2.44M Buy
82,000
+18,000
+28% +$563K 2.62% 12
2016
Q4 		$2.21M Buy
+64,000
New +$2.2M 1.58% 17

Other funds holding TRIB

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Fondren Management's TRIB Position: Q2 2020 in Review

Fondren Management sold out of Trinity Biotech (TRIB) in Q2 2020, closing a stake of 46,000 shares — an estimated $253K sold.

Fondren Management first reported a position in TRIB in Q4 2016 and held it in 13 quarters. The position peaked at $2.44M in Q1 2017. 27 funds tracked by Wall St. Rank hold TRIB as of Q2 2020.

  • Fondren Management reported no remaining Trinity Biotech position as of Q2 2020 after selling out during the quarter.
  • Fondren Management sold 46,000 Trinity Biotech shares in Q2 2020, an estimated $253K.
  • Fondren Management first reported a position in Trinity Biotech in Q4 2016 and held it in 13 quarters.
  • Fondren Management's Trinity Biotech position peaked at $2.44M in Q1 2017.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2020.

Based on Fondren Management's 13F filing for Q2 2020, filed 14 Aug 2020.